Search is Powered by Google
Bipolar News

Janssen-Cilag International N.V. Withdraws Its Application For An Extension Of Indication For Invega (paliperidone)

Main Category: Bipolar
Also Included In: Regulatory Affairs / Drug Approvals;  Psychology / Psychiatry;  Mental Health
Article Date: 20 Dec 2008 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

The European Medicines Agency (EMEA) has been formally notified by Janssen-Cilag International N.V. of its decision to withdraw its application for an extension of indication for the centrally authorized medicine Invega (paliperidone) prolonged-release tablets.

Invega was expected to be used for the treatment of acute manic episodes associated with bipolar I disorder.

Invega was first authorised in the European Union on 25 June 2007. It is currently indicated for the treatment of schizophrenia.

The application for the extension of indication for Invega was submitted to the EMEA on 10 September 2008.

In its official letter, the company stated that the withdrawal was based on the feedback from the early evaluation indicating that the data provided were not sufficient to support approval for this indication and the company's view that it was not in a position to adequately address this issue at that time.

Invega continues to be authorised for the currently approved indication.

More information about Invega and the state of the scientific assessment at the time of the withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the EMEA website in due course.

Notes

1. Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage.

2. More information about Invega is available in the European Public Assessment Report (EPAR): see here.

3. This press release, together with other information on the work of the EMEA, can be found on the EMEA website: http://www.emea.europa.eu.

European Medicines Agency

View drug information on Invega.





Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Common Causes Of Schizophrenia And Bipolar Disorder
18 Jan 2009
Schizophrenia and bipolar disorder have the same genetic causes, according to a study from Karolinska Institutet published today in the highly respected journal The Lancet. The results throw the current separate...


Naps Aren't Just for Kids Anymore
Naps Aren't Just for Kids Anymore

A power nap may be the answer to the mid-day slump. Research suggests naps improve productivity, mental function, and motor function. They also may improve cardiovascular health.

more videos are available in our health videos section.